Synexus Pushes Ahead with Central & Eastern Europe Expansion
Synexus has announced plans to open three new research centers in Bulgaria, Poland and Romania.
Synexus has announced plans to open three new research centers in Bulgaria, Poland and Romania, bringing the company’s total to nine centers in Central & Eastern Europe and a total network of 25 across Europe and Africa.
The population of Central and Eastern Europe exceeds that of either the US or the five largest Western European markets combined, and it also has excellent healthcare professionals, according to the U.K.-headquartered recruitment specialist.
“This will help us to provide much greater support to the global pharmaceutical industry,” noted CEO Christophe Berthoux. “Since we opened our first centre in Poland in 2006 we have had an ongoing programme of investment in the region.”
The new Polish facility is the company’s largest research center in the world. It occupies 1000 m2 at Beniowskiego Street in Gdansk. Magdalena Przekwas-Jaruchowska, M.D., the facility’s director, oversaw the opening ceremony, which included representatives from the local authority, the British Embassy, the medical university and patients’ associations.
Romania’s new 820 m2 center is based in Bucharest, which has a population of two million. The country has been part of Synexus’ development plans since early 2000, as the total population is over 20 million and the number of new clinical trials granted approval during the last five years is at least 200, according to the company.
In Sofia, Bulgaria, the total area of the new center is 650 m2, and it has eight medical rooms, two administration rooms, monitoring and meeting rooms and other areas. This facility aims to offer its patients access to new drugs in the fields of pulmonology, rheumatology, neurology, endocrinology, cardiology, gastroenterology and dermatology.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
